Navigation Links
Oncomodulin in Medical News

Alseres Shares Begin Trading on the Pink Sheets OTC Market

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. F...

Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. F...

Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. F...

Alseres Pharmaceuticals, Inc. Announces $200,000 Financing

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc.'s Chairman, Peter Savas, Reviews Company's Progress in its Annual Letter to Stockholders

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
Oncomodulin in Medical Technology

Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial

...n a Phase I/IIa clinical trial. The Company's research and pre- clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The company...
Oncomodulin in Biological Technology

Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. Raises $5 Million

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights

...ies in which other of our regenerative technologies, including Inosine, oncomodulin and other compounds, are being tested in parallel in a series of models...ograms include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs direct...

Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
Other Tags
(Date:7/10/2014)... July 10, 2014 Ticketability.com has a wide ... now Paul McCartney tickets for San Diego are being added ... Diego since 1976, and the newly added September 28 show ... , Click Here to view the selection of ... Petco Park will become available to the general public on ...
(Date:7/10/2014)... D.C. (PRWEB) July 10, 2014 One ... for Bangladesh Worker Safety announced today it will extend ... to four months’ wages for workers displaced as a ... To date, Alliance inspections have resulted in the closure ... in all five cases, raising immediate safety concerns. In ...
(Date:7/10/2014)... 2014 According to a new ... Platforms (Land, Airborne, Naval), Application (Software Defined Radios, ... Geography (North America, Asia-Pacific, Europe, the Middle East ... by MarketsandMarkets, the market is estimated to be ... register a CAGR of 5.56% to reach $39.52 ...
(Date:7/10/2014)... In his latest blog post at http://www.perwickstrom.com , ... Wickstrom has listed 5 ways to follow-up without being ... get information or sometimes even just return an inquiry, ... a skill that most people don’t have,” commented Per ... dialogue moving without coming across as annoying – let ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2
(Date:7/10/2014)... scientists have discovered that scorpions create a platform in ... hunt. , As ectothermic animals, scorpions rely on ... researchers believe that this platform provides a safe, warm ... before they leave their hiding places to forage at ... ( Scorpio maurus palmatus ) in Israel,s Negev desert ...
(Date:7/10/2014)... Amyloid diseases, such as Alzheimer,s disease, type ... share the common trait that proteins aggregate into ... vitro studies have found that neither the amylin ... toxic. New evidence using two-dimensional infrared (2D IR) ... amylin aggregation pathway that may explain toxicity, opening ...
(Date:7/10/2014)... Satellite or GOES-West satellite spotted smoke over the ... Canada,s Northwestern Territories. , At 1200 UTC (8 ... this image of the brownish-colored haze created by ... all the way into South Dakota. This image ... NASA Goddard Space Flight Center, Greenbelt, Md. ...
Breaking Biology News(10 mins):Scorpions are master architects, according to new research from Ben-Gurion University 2New technology reveals insights into mechanisms underlying amyloid diseases 2
Other Contents